Hodgkin Disease, Pediatric, Hodgkin Disease Recurrent, Hodgkin Disease Refractory, Hodgkin Lymphoma, Adult
Conditions
Keywords
r/r Hodgkin Lymphoma, CD30, adult, pediatrics
Brief summary
This is a two-part, Phase 2, multicenter, open-label, single arm study to evaluate the safety and efficacy of autologous CD30.CAR-T in adult and pediatric subjects with relapsed or refractory CD30+ classical Hodgkin Lymphoma.
Detailed description
The Pilot part of the study will evaluate the safety, tolerability, and preliminary antitumor efficacy of CD30.CAR-T. The Pivotal part of the study will evaluate antitumor efficacy and further evaluate safety and tolerability. All study eligibility requirements, assessments, procedures, and follow-up are the same for patients in both Pilot and Pivotal parts of the study. Subjects who meet eligibility criteria will have their blood drawn by leukapheresis for manufacture the CD30.CAR-T cells. Subjects are allowed bridging chemotherapy, as per Investigator choice, while waiting for production of CD30.CAR-T. Lymphodepletion (LD) with fludarabine and bendamustine will be administered for 3 consecutive days starting on Day -5 to Day -3, prior to CD30.CAR-T infusion, which will be administered on Day 0 as a single IV infusion. Depending on disease status, eligible subjects may receive up to a total of two CD30.CAR-T infusions at the same dose, each with preceding LD chemotherapy. Subjects will be closely monitored for safety and efficacy throughout the Treatment Period until the end of study (EOS) visit at Month 24. Subjects will be followed for survival, withdrawal of consent or study closure, whichever occurs first. Health Related Quality of Life assessments will also be collected throughout the study. After the EOS visit, subjects will enter the long-term follow-up phase (LTFU) which will include survival follow-up, additional safety, efficacy and biomarker assessments, as clinically indicated.
Interventions
DRUGCD30.CAR-T
Autologous CD30.CAR-T cells infused on Day 0 after the completion of lymphodepleting chemotherapy.
DRUGFludarabine
Lymphodepletion chemotherapy (30 mg/m2/day) for 3 consecutive days
DRUGBendamustine
Lymphodepletion chemotherapy (70 mg/m2/day) for 3 consecutive days
Sponsors
Tessa Therapeutics
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Eligibility is determined prior to blood collection . Patients must satisfy the following criteria to be enrolled in the study: 1. Signed Informed Consent Form 2. Male or female patients who are 12 - 75 years of age 3. Histologically confirmed classical Hodgkin Lymphoma 4. Relapsed or refractory cHL that has failed at least 3 prior lines of therapy, including: * chemotherapy * BV and/or * PD-1 inhibitor Patients may have previously received an autologous and/or allogeneic stem cell transplant 5. CD30-positive tumor 6. At least 1 measurable lesion according to The Lugano Classification 7. Laboratory parameters: Hematological, renal and hepatic functions, and coagulation parameters * Hgb ≥ 8.0 g/dL * Total bilirubin ≤ 1.5 × ULN * AST and ALT ≤ 5 × the ULN * CrCl \> 45 mL/min * ANC \>1,000/µL * Platelets \>75,000/µL * PT or INR ≤ 1.5 × ULN; PTT or aPTT ≤ 1.5 × ULN 8. ECOG PS of 0 to 1 or equivalent \[either Karnofsky PS (for patients ≥ 16 year of age) or Lansky PS (for patients \< 16 years of age)\] 9. Anticipated life expectancy \> 12 weeks
Exclusion criteria
1. Evidence of lymphomatous involvement of central nervous system (CNS) 2. Presence of clinically relevant or active seizure disorder, stroke, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with central nervous system (CNS) involvement 3. Active uncontrolled bleeding or a known bleeding diathesis 4. Inadequate pulmonary function defined as pulse oximetry \< 90% on room air 5. ECHO or MUGA with LVEF \< 45% 6. On-going treatment with immunosuppressive drugs or chronic systemic corticosteroids 7. Having received: * Anti-CD30 antibody-based therapy within 4 weeks prior to CD30.CAR-T infusion * Prior investigational CD30.CAR-T * CD30 bispecific agent within 8 weeks prior to CD30.CAR-T infusion * Autologous HSCT within 90 days or allogeneic HSCT within 180 days prior to CD30.CAR-T infusion 8. Currently receiving any investigational agents within 4 weeks prior to study enrollment; or received any tumor vaccines within 6 weeks prior to CD30.CAR-T infusion 9. Active acute or chronic graft versus host disease (GVHD) requiring immune suppression regardless of grade 10. Evidence of human immunodeficiency virus (HIV) infection 11. Seropositive for and with evidence of active viral infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) 12. Unresolved \> Grade 1 non-hematologic toxicity associated with any prior treatments 13. History of hypersensitivity reactions to murine protein-containing products or other product excipients 14. Symptomatic cardiovascular disease: Class III or IV according to the New York Heart Association (NYHA) Functional Classification 15. Active second malignancy or history of another malignancy within the last 3 years 16. Women who are pregnant or intending to become pregnant; women who are breastfeeding; persons with procreative potential not using and not willing to use 2 highly effective methods of contraception 17. Any other serious, life-threatening, or unstable preexisting medical conditions
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pilot: Safety of autologous CD30.CAR-T | Minimum 24 months post-CD30.CAR-T infusion | Adverse events |
| Pivotal: Anti-tumor effect of autologous CD30.CAR-T using objective response rate (ORR) as assessed by an Independent Radiology Review Committee (IRRC) per the Revised Criteria for Response Assessment: The Lugano Classification (Cheson, 2014) | As early as 6 weeks after CD30.CAR-T treatment | ORR |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pilot: Progression Free Survival | Minimum 24 months post-CD30.CAR-T infusion | PFS |
| Pilot: Overall Survival | Minimum 24 months post-CD30.CAR-T infusion | OS |
| Pilot: Health Related quality of life (HRQoL) questionnaire | Minimum 24 months post-CD30.CAR-T infusion | QoL |
| Pivotal: Number of patients with adverse events as a measure of safety and tolerability of CD30.CART cells | As early as 6 weeks after CD30.CAR-T treatment | Adverse events |
| Pilot: Antitumor efficacy of autologous CD30.CAR-T using objective response rate (ORR) as assessed by an Independent Radiology Review Committee (IRRC) per the Revised Criteria for Response Assessment: The Lugano Classification (Cheson et al., 2014) | As early as 6 weeks after CD30.CAR-T treatment | ORR |
| Pivotal: Progression Free Survival (PFS) | Minimum 24 months post-CD30.CAR-T infusion | PFS |
| Pivotal: Duration of Response (DOR) | Minimum 24 months post-CD30.CAR-T infusion | DOR |
| Pivotal: Overall Survival | Minimum 24 months post-CD30.CAR-T infusion | OS |
| Pivotal: Health Related quality of life (HRQoL) questionnaire | Minimum 24 months post-CD30.CAR-T infusion | HRQoL |
| Pivotal: Objective response rate (ORR as assessed by IRRC) per the Revised Criteria for Response Assessment: The Lugano Classification (Cheson, 2014) | Minimum 24 months post-CD30.CAR-T infusion | ORR |
| Pilot: Duration of Response | Minimum 24 months post-CD30.CAR-T infusion | DOR |
Countries
United States
Outcome results
None listed